Open AccessIndustry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy
Author(s) -
Stacie Ittershagen,
Solveig G. Ericson,
Lamis Eldjerou,
Ali Shojaee,
Eric Bleickardt,
Manisha Patel,
Tetiana Taran,
Oezlem Anak,
Charlene Hall,
Mimi Leung,
Deborah Roccoberton,
Florence Salmon,
Miriam Fuchs,
Vadim Romanov,
David Lebwohl
Publication year - 2019
Publication title -
current hematologic malignancy reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.299
H-Index - 35
eISSN - 1558-822X
pISSN - 1558-8211
DOI - 10.1007/s11899-019-0498-6
Subject(s) - chimeric antigen receptor , medicine , immunotherapy , hematology , cytokine release syndrome , clinical trial , oncology , cancer
We describe the significant technological leap from bench to bedside that was achieved through a strong academic-industry collaboration between dedicated clinicians and researchers at the University of Pennsylvania, the Children's Hospital of Philadelphia, and Novartis to commercialize the chimeric antigen receptor T cell (CAR-T) therapy tisagenlecleucel (CTL019; Kymriah®; Novartis Pharma AG, Basel, Switzerland).